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A b s t r a c t
Background: Heart failure (HF) is a chronic disease with poor prognosis, being the final stage of many cardiovascular condi-
tions and often requiring hospitalisation.
Aim: The aim of the study was to evaluate the effect of hospitalisation length on prognosis in patients with HF.
Methods: Between February 2012 and January 2013, in 32 cardiology centres in Poland, 1126 HF patients were included in 
the EURObservational Research Programme on Heart Failure Registry. A total of 765 persons were hospitalised. A follow-up 
(FU) of 414 ± 121 days was conducted.
Results: The median length of hospitalisation was seven days (interquartiles 25th–75th; 4–11), also for new onset (14.5% of 
patients) and chronic HF (seven days, 5–11 and 4–11, respectively). Patients who died during FU (16.5%) and those who 
survived were hospitalised for a median of eight days (6–12) and seven days (4–10), respectively (p < 0.001). Patients hospi-
talised for 8–21 and 22 or more days had an increased risk of death after discharge (hazard ratio [HR] 1.70; 95% confidence 
interval [CI] 1.16–2.49 and HR 2.20; 95% CI 1.04–4.67, respectively) than those hospitalised for up to seven days. Predictors 
of death in the FU period in multivariate analysis included age (1.02; 95% CI 1.01–1.04), history of chronic kidney disease 
(CKD) (HR 1.55; 95% CI 1.05–2.30), and New York Heart Association (NYHA) class III (HR 2.52; 95% CI 1.22–5.18) and IV 
(HR 4.77; 95% CI 2.32–9.82) at admission. Patients hospitalised for 22 or more days were more often male (77%), and with 
a history of CKD (34%). At admission they had lower systolic (118 ± 25 mm Hg) and diastolic (72 ± 12 mm Hg) blood pres-
sure, higher NT-proBNP (9191 ± 8776 pg/mL), lower serum sodium level (137 ± 5 mmol/l), as well as lower ejection fraction 
before and during hospital stay (30 ± 12% and 34 ± 14%, respectively; p < 0.05 for all factors). Factors that influenced 
the length of hospital stay included history of CKD (p < 0.001), current malignancy (p = 0.026), and infection at admission 
(p < 0.001). Most of the admitted patients presented NYHA class III (45%). The poorer the NYHA class at admission, the 
longer the patient’s hospital stay (p < 0.001). 54% patients were re-admitted to the hospital during FU. Patients re-admitted 
and not re-admitted during the one-year FU had the same median duration of the index hospitalisation (seven days; 4–10 and 
4–11, respectively; p = 0.957).
Conclusions: Patients with HF hospitalised for 22 or more days, in comparison to patients hospitalised for less than eight 
days, had double the risk of death during FU. We believe that prolonged hospitalisation might be regarded as a marker of 
poor prognosis in patients with acute HF.
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INTRODUCTION
Heart failure (HF) is a chronic disease, which is the final stage 
of many cardiovascular (CV) conditions that vary in different 
parts of the world [1]. Despite the fact that there is a decline in 
the HF hospitalisation rate [2, 3], many persons will live with 
HF syndrome for many years with episodes of exacerbation 
requiring hospital admissions. Recurrent and prolonged hospi-
talisations impose a substantial clinical and economic burden 
on patients, caregivers, physicians, and health systems [4, 5]. 
The mean (or median) length of hospital stay in HF ranges 
from 6 to > 10 days in Europe [6, 7] and 3–9 days in the 
United States [8], although it has decreased in the last three 
decades. The differences in the length of hospital stay prob-
ably reflect varying care management, health care systems, 
and improved prevention of HF [2, 4, 9–13].
The aim of our study was to evaluate the effect of the 
length of hospital stay on the risk of death and re-admission 
during follow-up (FU) as well as clinical status at discharge in 
patients hospitalised with an acute new onset HF or exacer-
bation of HF. We also evaluated factors affecting the length 
of hospital stay as well as predictors of mortality in the FU.
It would be of great value to understand the implication 
of inpatient care on HF prognosis. If we knew which factors 
influenced the length of hospitalisation and the patient’s clini-
cal status, as well as the impact of these factors on exacerba-
tion of the disease or death, we would be able to implement 
appropriate surveillance in the post-discharge period, not only 
to prevent death, but also to alleviate symptoms and maintain 
a good quality of life. The impact of a longer hospital stay on 
mortality rate and rehospitalisation were one of the issues to 
be evaluated in the EURObservational Research Programme: 
The HF Pilot Survey [10].
METHODS
Study population
The EURObservational Research Programme on Heart Failure 
Registry is a large, prospective, multi-centre (21 countries 
— members of the European Society of Cardiology [ESC]), 
long-term registry of HF patients. 
The Polish part of the EURObservational Research Pro-
gramme Registry included 1126 HF patients treated between 
February 2012 and January 2013 at 32 cardiology centres. A total 
of 765 patients were hospitalised, and follow-up was conducted.
The inclusion criteria were previously described [14]. 
Briefly, the national cardiology societies were asked to select 
units dealing with HF inpatients and outpatients. All patients 
aged 18 years or more, who met diagnostic criteria for a new 
onset or worsening HF, admitted to hospital or seen by car-
diologists in ambulatory care were included. There were no 
specific exclusion criteria other than the lack of consent. The 
patients’ characteristics included clinical status at admission, 
discharge, and FU, the aetiology of HF, comorbidities, bio-
chemical parameters, pharmacological and device therapy, 
and — during FU — data about rehospitalisation and current 
pharmacological treatment. 
Statistical analysis
For descriptive analyses, median and interquartile range (IQR 
25th – 75th percentiles) or mean and standard deviation (SD) 
are presented for continuous variables, and percentages, for 
categorical variables. Length of hospitalisation is reported as 
median because it does not follow normal distribution. Sub-
groups are compared by Mann-Whitney U test.
To investigate the influence of the effect of hospitalisation 
on HF prognosis, we divided inpatients into three groups: 
hospitalised for 1–7 days (n = 419), 8–21 days (n = 305), 
and 22 days or more (n = 41). We determined such cut-off 
points because the median length of stay was seven days, and 
22 days was the 95th percentile. 
For comparison of more than two groups, Kruskall-Wallis 
with post-hoc Dunn’s test was used. Cox proportional hazard 
model was used to identify the risk of death after discharge. 
The results were presented as hazard ratio (HR) and 95% 
confidence interval (CI). The significant factors found in uni-
variate analysis were taken into multivariate analysis (stepwise 
forward selection). All tests were considered significant at 
p < 0.05. Analyses were performed using Statistica version 10 
(StatSoft Inc.) software. 
RESULTS
Patient characteristics
A total of 765 patients were included, of which 516 (68%) 
were male. The mean age was 69 ± 12 years. 111 (14.5%) 
patients were newly diagnosed with acute HF, whereas 
256 (33.5%) patients with chronic status previously diagnosed 
in ambulatory circumstances were admitted for the first time. 
Twenty-two (2.9%) patients died during hospitalisation.
The mean time from discharge to FU date was 
414 ± 121 days. Fifty-four (7%) patients were lost to FU. Of 
the 689 who were contacted, 114 (16.5%) died during the 
entire FU period, and the one-year mortality rate was 11.8%.
Hospitalisation stay duration
The median length of hospitalisation was seven days (4–11), 
both for men and women, as well as for new onset and chronic 
HF (seven days, 4–12, 4–10, 5–11, 4–11, respectively). Pa-
tients who were re-admitted at least once during the FU and 
patients not re-admitted also had the length of index hospital 
stay of seven days (4–10 and 4–11, respectively). Patients 
who died during the FU period, in comparison to those who 
survived, were hospitalised for eight days (6–12) and seven 
days (4–10), respectively (p < 0.001). 
The patients’ basic characteristics according to the length 
of hospital stay are presented in Table 1. Factors from patients’ 
medical history (Table 1), which affected the length of hospital 
stay, were as follows: a history of chronic kidney disease (CKD) 
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Table 1. Characteristics of patients with acute heart failure (HF) depending on the length of hospital stay. Patients who died 
during hospitalisation and patients lost to follow-up were excluded.
Parameter No. of  
patients
All (%) Length of stay (in days) p
1–7 8–21 22 or more
Age 689 69±12 69 ± 12 69 ± 13 68 ± 10 0.601
Male 461 67% 63% (239) 71% (195) 77% (27) 0.028
Weight [kg] 687 81 ± 17 80 ± 17 82 ± 18 80 ± 15 0.473
Medical history
History of HF prior to admission 589 86% 86% (327) 86% (233) 83% (29) 0.622
HF aetiology:
   IHD documented by CA 
   Valve disease
   Dilated cardiomyopathy
   IHD not documented by CA
   Tachycardia-related cardiomyopathy
   HFpEF
   Hypertensive HF
   Other type
285
91
105
97
22
22
46
21
41%
13%
15%
14%
3%
3%
7%
3%
41% (155)
15% (57)
15% (59)
12% (45)
4% (17)
4% (14)
7% (26)
2% (8)
42% (115)
12% (32)
14% (39)
17% (47)
2% (4)
3% (8)
6% (18) 
4% (10)
43% (15)
6% (2)
20% (7)
14% (5)
3% (1)
0% (0)
6% (2)
8% (3)
0.918
0.228
0.662
0.146
0.082
0.675
1.000
0.061
Myocardial infarction or angina 374 54% 52% (199) 58% (157) 51% (18) 0.385
Atrial fibrillation 324 47% 46% (177) 48% (130) 49% (17) 0.498
Hypertension (treatment) 496 72% 73% (277) 72% (197) 63% (22) 0.541
Diabetes 239 35% 33% (125) 37% (102) 34% (12) 0.633
COPD 107 16% 15% (56) 18% (49) 6% (2) 0.310
CKD (creatinine level > 1.5 mg/dL) 194 28% 24% (91) 33% (91) 34% (12) 0.021
Stroke/TIA 75 11% 10% (37) 14% (37) 3% (1) 0.088
Depression 36 5% 5% (20) 5% (14) 6%(2) 0.989
Current malignant disease 25 4% 3% (11) 4% (12) 6% (2) 0.474
Infection at admission 105 15% 9% (35) 23% (62) 23% (8) < 0.001
Previous treatment:
ACEI or ARB 499 72% 77% (294) 65% (178) 77% (27) 0.002
Beta-blocker 530 77% 78% (294) 76% (208) 80% (28) 0.183
Oral diuretics 489 70% 69% (262) 74% (201) 74% (26) 0.029
Aldosterone antagonists 328 48% 47% (178) 48% (131) 54% (19) 0.534
Presentation at admission:
Pulmonary rales 428 62% 55% (211) 72% (197) 57% (20) < 0.001
Peripheral oedema 348 51% 48% (181) 57% (156) 31% (11) 0.003
Systolic BP [mm Hg] 689 130 ± 27 131 ± 27a 128 ± 27b 118 ± 25c 0.016
Diastolic BP [mm Hg] 688 78 ± 15 79 ± 14a 76 ± 15b 72 ± 12c < 0.001
Labs at admission:
NT-proBNP [pg/mL] 259 5729 ± 7272 3789 ± 4348b 7460 ± 9058a 9191 ± 8776a < 0.001
Serum sodium [mmol/L] 683 139 ± 4 139 ± 4a 138 ± 5b 137 ± 5c 0.008
Serum potassium [mmol/L] 684 4.5 ± 0.6 4.5 ± 0.6 4.5 ± 0.6 4.5 ± 0.5 0.735
Intravenous treatment during hospital stay:
Inotropic support 80 13% 10% (38) 15% (42) 23% (8) 0.148
Diuretics 391 57% 52% (197) 63% (172) 63% (22) 0.062
Nitrates 84 12% 10% (40) 15%(42) 6% (2) 0.081
NYHA status (mean ± standard deviation):
NYHA class at admission 687 3.1 ± 0.7 2.9 ± 0.7b 3.3 ± 0.7a 3.0 ± 0.7b < 0.001
NYHA class at discharge 689 2.3 ± 0.6 2.2 ± 0.5b 2.4 ± 0.6a 2.3 ± 0.5a, b < 0.001
NYHA class during FU 545 2.2 ± 0.7 2.2 ± 0.6 2.3 ± 0.7 2.3 ± 0.6 0.392
Ejection fraction [%]:
Last known 469 36 ± 15 38 ± 15a 34 ± 15b 30 ± 12b 0.002
During hospital stay 597 38 ± 15 40 ± 15a 36 ± 16b 34 ± 14b 0.005
a, b, cMeans that groups followed by the same letter do not differ significantly; ACEI — angiotensin converting enzyme inhibitor; ARB — angioten-
sin II receptor blocker; BP — blood pressure at admission; CA — coronary angiogram; CKD — chronic kidney dysfunction; COPD — chronic ob-
structive pulmonary disease; FU — follow-up; HF — heart failure; HFpEF — heart failure with preserved ejection fraction; IHD — ischaemic heart 
disease; NT-proBNP — N-terminal pro B-type natriuretic peptide; NYHA — New York Heart Association; TIA — transient ischaemic attack 
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(p < 0.001), current malignancy (p = 0.026), and infection 
at admission (p < 0.001). 
NYHA class status 
Most of the patients admitted to the hospital presented New 
York Heart Association (NYHA) class III (45%), and the mean 
NYHA value at admission was 3.1 ± 0.7. At discharge they 
were NYHA class II (63%) and 2.3 ± 0.6 (Table 1). The me-
dian duration of analysed hospital stay in relation to NYHA 
status is presented in Table 2. The poorer the NYHA class at 
admission, the longer the patient was hospitalised (p < 0.001).
Rehospitalisations
Fifty-four per cent of patients (345 out of 641) were re-ad-
mitted for any cause at least once and 46% were re-admitted 
more than once during FU. The mean time from discharge 
to the first CV or HF rehospitalisation within a year was 
137 ± 108 days. The 30-day CV/HF re-admission rate was 
5%, and, depending on the length of index hospital stay, 5% 
of patients hospitalised for 1–7 days and 8–21 days as well 
as 3% of patients hospitalised for ≥ 22 days were readmitted. 
Generally, the median duration of the index hospital stay in re-
hospitalised patients was seven days (4–10) and did not differ 
from the stay length of those who were not rehospitalised (up 
to 12 months of FU; median seven days [4–11], p = 0.957).
Prognosis  
In patients hospitalised for 8–21 days and ≥ 22 days, the 
risk of death during FU was increased (HR 1.70; 95% CI 
1.16–2.49 and HR 2.20; 95% CI 1.04–4.67, respectively; 
Fig. 1, Table 3). 
The analysis of the one-year prognosis according to the 
length of hospitalisation revealed that in patients hospitalised 
for 8–21 days the death rate was 14.8% (n = 45), ≥ 22 days 
— 14.6% (n = 6), and 1–7 days — 6.9% (n = 29). 
In the univariate analysis, apart from prolonged duration 
of stay, predictors of death in FU are presented in Table 3. In 
a multivariate analysis the significant predictors of death were 
only age, NYHA class III and IV, and history of CKD (Table 4). 
The Kaplan-Meyer curves for survival probability during 
FU (age and NYHA class at admission) are presented in Fig-
ure 2. There was a significant difference over time between 
NYHA status at admission (p < 0.001). 79% of patients with 
NYHA IV, 89% with NYHA III, and 97% with NYHA II were 
still alive one year after discharge (Fig. 2A). Outcome over time 
was also significantly different, depending on age (per 10-year 
increase; p = 0.013, Fig. 2B). 82% of patients > 80 years of 
age and, on the other hand, 93% of patients between 51 and 
60 years of age survived a one-year FU. 
DISCUSSION
This study evaluated a large group of Polish hospitalised 
patients with acute new onset or exacerbation of chronic 
HF. Existing research on length of hospital stay is very limited 
and focuses on economic outcomes, predictors of length of 
hospital stay, or effect on quality-of-care measures [9, 13, 
15–17]. To the best of our knowledge, this is the first analysis of 
a voluntary large registry indicating that the length of hospitali-
sation might be regarded as a marker of poor prognosis in HF. 
The median length of hospital stay in the study group 
of patients was seven days (4–11) and was shorter than that 
reported in two previous European surveys: EuroHeart Failure 
Survey (EHFS) II and ESC-HF Pilot (nine days [IQR 5–11] and 
eight days [IQR 6–14], respectively) [10, 12]. In these studies, 
patients from Eastern European countries (Poland and Ro-
mania) compared to inpatients from Northern, Western, and 
Southern European countries had a better one-year outcome 
(all-cause mortality and re-hospitalisation rate) [18]. This sug-
gests that Polish patients were probably “less ill” than patients 
hospitalised in other parts of Europe and, as a result, were 
hospitalised for a shorter period. Conversely, in other studies 
Table 2. The influence of New York Heart Association (NYHA) 
status on the length of the index hospitalisation: at admission, 
discharge, and during follow-up. Data in median days and 
interquartiles (25–75)
NYHA class Length of index hospitalisation  
according to NYHA class (in days)
Admission Discharge Follow-up
I – 6 (4–9) 7 (2–11)
II 5 (2–9)* 6 (4–10)* 6 (4–9)*
III 7 (4–10)* 8 (5–13)* 7 (5–11)* 
IV 8 (6–13)* 10 (6–14) 7 (5–10)
*Means that particular comparison between the length of hospital 
stay in patients with given NYHA classes: at admission, discharge, and 
follow-up are statistically significant (Kruskall-Wallis test), e.g. at dis-
charge there is a statistically significant difference between the length 
of hospital stay between patients with NYHA class II and III.
Figure 1. The effect of the length of hospital stay on the risk 
of death during follow-up
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Table 3. Univariate analysis of predictors of death in heart failure (HF) patients during follow-up
Variable HR (95% CI) p
Age (per one year increase) 1.03 (1.01–1.05) < 0.001
Female gender 0.95 (0.64–1.41) 0.815
Weight [kg] 0.09 (0.97–0.99) 0.049
Body mass index [kg/m2] 0.96 (0.93–1.00) 0.076
Length of hospitalisation: 
    8–21 days
    ≥ 22 days
1.70 (1.16–2.49)
2.20 (1.04–4.67)
0.006
0.038
COPD 1.54 (0.99–2.40) 0.055
History of CKD (creatinine >1.5 mg/dL) 1.82 (1.26–2.64) 0.001
Depression 1.86 (0.97–3.56) 0.061
Clinical presentation at admission (in comparison to decompensated HF):
    Hypertensive HF
    Right HF
    ACS/HF
    Cardiogenic shock
    Pulmonary oedema
0.52 (0.21–1.29)
0.95 (0.41–2.19)
0.82 (0.42–1.58)
1.29 (0.40–4.13)
1.37 (0.71–2.65)
0.161
0.918
0.559
0.663
0.343
Inotropic support during hospitalisation 3.30 (2.00–4.95) < 0.001
Nitrates IV during hospitalisation 1.41 (0.83–2.40) 0.198
Diurectis IV during hospitalisation 2.53 (1.65–3.88) < 0.001
NYHA class at admission (in comparison to NYHA II):
    NYHA III
    NYHA IV
2.93 (1.43–5.98)
5.93 (2.93–11.97)
0.003
< 0.001
Ejection fraction during hospital stay [%] 0.98 (0.97–0.99) 0.004
LBBB in ECG at admission 0.85 (0.46–1.56) 0.614
QTc-length in ECG at admission (Bazett formula [ms]) 1.01 (1.00–1.01) 0.011
ACS — acute coronary syndrome; CI — confidence interval; COPD — chronic obstructive pulmonary disease; CKD — chronic kidney dysfunction; 
ECG — electrocardiogram; HR — hazard ratio; i.v. — intravenously; LBBB — left bundle branch block; NYHA — New York Heart Association
Table 4. Multivariate analysis of predictors of death in heart 
failure patients during follow-up. Only statistically significant 
predictors are presented 
Variable HR (95% CI) p
Age (per one year increase) 1.02 (1.01–1.04) 0.001
NYHA class III at admission
NYHA class IV at admission
(comparing to NYHA class II)
2.11 (1.00–4.47)
3.83 (1.77–8.30)
0.049
< 0.001
History of CKD  
(creatinine > 1.5 mg/dL) 
1.56 (1.05–2.31) 0.026
CI — confidence interval; CKD — chronic kidney dysfunction; HR — 
hazard ratio; NYHA — New York Heart Association
In some studies, patients were enrolled in a single centre and 
were significantly older, while in others some of them were 
admitted to perform scheduled elective procedures. 
There are few studies concerning factors affecting the 
length of hospital stay in HF patients. In most of them, 
CKD, ischaemic heart disease, diabetes, chronic obstruc-
tive pulmonary disease, anaemia, female gender, peripheral 
congestion, poor NYHA class, low blood pressure (BP), and 
social problems, were predictors of prolonged hospitalisation 
[7, 9, 15–17, 20]. In our study, only CKD, current malignant 
disease, and infection were found to prolong the length of stay. 
Nevertheless, patients who were hospitalised for ≥ 22 days, 
compared to those hospitalised for ≤ 7 and 8–21 days, had 
significantly lower BP, poorer laboratory test results (lower 
sodium, higher N-terminal pro B-type natriuretic peptide 
[NT-proBNP]) at admission, and lower ejection fraction be-
fore and during hospital stay. Surprisingly, apart from CKD, 
there was no difference in the incidence of comorbidities 
between the study groups. In addition, patients hospitalised 
from Europe, the United States, and New Zealand, the median 
length of hospital stay was shorter [9, 15, 17, 19]. It is difficult 
to compare such studies because of different inclusion and 
exclusion criteria as well as varying health services availability. 
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for ≥ 22 days were generally more often treated according 
to ESC guidelines before admission (we did not evaluate any 
dosage of drugs).
We found that poor NYHA class both at admission 
and discharge was associated with prolonged hospital stay. 
Our results corroborate with the study on elderly inpatients 
(≥ 65 years of age) from Spain [9], where only poorer NYHA 
functional class (OR 1.69, 95% CI 1.13–2.54) and female 
gender (OR 1.64, 95% CI 1.04–2.58) were independent 
predictors of a subsequent longer stay. 
It is still unknown how long a hospital stay due to HF 
exacerbation should be to prevent re-admissions [15]. As pre-
sented here, both re-admitted and non-readmitted patients 
had the same duration of index hospital stay. The length of 
stay during an HF hospitalisation of more than seven days 
was shown to be a significant predictor of re-admission in 
Medicare beneficiaries (OR, 1.32; 95% CI, 1.24–1.41) [21]. 
There are some differences in studies concerning post-dis-
charge prognosis in HF. In Scotland, a decline in short- and 
medium-term (one-year) fatality due to HF hospitalisation 
(1986–2003) was observed [3]. In our study, all-cause mor-
tality at one year of FU was lower than in the ESC-HF Pilot 
Study (11.8% at one-year and 16.5% during the entire FU 
period in our study vs. 17.4% in ESC-HF). Of the 2891 pa-
tients participating in EHFS II, 241 (8.1%) died up to three 
months after hospital discharge and 542 (20.5%) died within 
12 months of FU. The higher overall mortality rate in these 
registries in comparison to our study was explained by the 
fact that hospitalised patients with HF in the Eastern part of 
Europe had a lower risk profile, were younger, had higher BP 
and more frequently had pharmacological treatment accord-
ing to the guidelines prescribed [10, 18]. What is important, 
in contrast to the ESC Pilot Survey and our study, only large 
hospitals with a wide range of health benefits participated in 
EHFS II [12, 22]. 
Still, little is known about post-discharge mortality risk 
when adjusted to length of hospitalisation. Our results sug-
gest that hospitalisation ≥ 22 days carried more than twice 
the risk of dying in the post-discharge period compared to 
hospitalisation of ≤ 7 days. A similar two-times higher mor-
tality for hospitalisation longer than 21 days was described 
in patients in the Candesartan in Heart Failure: Assessment 
of Reduction in Mortality and morbidity (CHARM) trial [23]. 
In fact, the median FU period in the CHARM study was 
38 months, so our findings might be underestimated. In an 
Italian population-based study [24], 30-day and one-year 
mortality after index discharge was significantly higher in 
patients hospitalised for 13 days or more (HR 1.82; 95% CI 
1.50–2.27 and HR 1.46; 95% CI 1.32–1.60, respectively). 
However, compared to our study, these patients were older 
(median 81 years of age), the median length of their hospital 
stay was 10 days, and only patients aged ≥ 50 years or over, 
newly hospitalised for HF were included. 
The significant predictors of death during FU in our study 
were mostly the same as those reported in other research and 
included age, impaired renal function, BP, sodium level, ejec-
tion fraction, sex, B-type natriuretic peptide or NT-proBNP, 
NYHA class, diabetes, and weight [25]. 
The prolonged duration of hospitalisation in our study 
was a predictor of poor prognosis, but only in the univariate 
analysis. Generally, patients with longer duration of stay have 
more comorbidities, higher severity of disease, and a greater 
number of procedures performed [13, 17, 19]. It is clear 
that decompensated HF patients who require longer hospi-
talisation are in a more serious condition and need longer 
treatment to recover [6, 22]. As a result, their short- and 
medium-term prognosis is worse than of those with shorter 
hospital stay. The effect of the duration of stay on prognosis 
is complex and subjectively determined because the criteria 
for hospital discharge are multiple and not strictly defined 
[19]. Moreover, a thorough analysis would require follow-up 
of the patients until their death and inclusion of every single 
hospitalisation and outpatient treatment records. Probably 
these are the reasons why only age, CKD, and poor NYHA 
Figure 2. Kaplan-Meyer survival curves for heart failure hospi-
talised patients according to New York Heart Association class 
status at admission (A) and age (in years) (B)
A
B
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class status at admission appeared to be predictors of death in 
the multivariate analysis in our study. Despite this, we believe 
that prolonged hospitalisation might be regarded as a marker 
of poor prognosis in hospitalised patients with acute HF. 
Limitations of the study
There are a number of limitations to the study. The HF diag-
noses were made by investigators and were not validated cen-
trally. We analysed only the index length of hospital stay. Other 
hospitalisations, before or after index one, probably had an 
effect on clinical status at admission and one-year prognosis.
Seven per cent of inpatients were lost to FU. Data about 
re-admissions in 102 out of 743 patients (13.7%) discharged 
from the hospital were missing. In the Polish part of the 
ESC-HF Pilot, incomplete data on readmission was about 
21% [26]. Incompleteness of data and representativeness is 
recognised as a limitation in observational studies [14]. There 
might be several causes of this fact in the present study. One of 
them is that 78% of patients were contacted by phone. Some 
of them could not answer, changed their phone number, or 
refused to answer. Those who responded could not remem-
ber the cause, the date, or the fact of hospital re-admissions. 
Twenty-two (3%) patients were admitted to the hospital 
with a diagnosis of HF with preserved ejection fraction (HF-
pEF) as the aetiology of the disease. Such a small number 
of patients was probably due to the fact that investigators 
tried to define the underlying cause of HF, and HFpEF was 
a diagnosis of exclusion.
So far, the registry presents only early and medium-term 
prognosis in HF patients.
CONCLUSIONS
Patients with acute HF hospitalised for 22 or more days, in 
comparison to patients hospitalised for less than eight days, 
had a doubled risk of death in FU. Those patients were more 
often male, had a history of CKD, and presented with a poorer 
clinical status at admission. Factors affecting length of hospital 
stay included history of CKD, current malignancy, and infec-
tion at admission. The significant predictors of death in FU in 
multivariate analysis were age, NYHA class III and IV, and his-
tory of CKD. We believe that prolonged hospitalisation might 
be regarded as a marker of poor prognosis in hospitalised 
patients with acute HF, but it requires a thorough analysis of 
the patient’s post-discharge period.
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Czas trwania hospitalizacji i rokowanie 
u pacjentów z niewydolnością serca
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S t r e s z c z e n i e 
Wstęp: Niewydolność serca (HF) jest przewlekłą chorobą charakteryzującą się złym rokowaniem. Stanowi stadium końcowe 
wielu schorzeń układu sercowo-naczyniowego, często wymaga również hospitalizacji. 
Cel: Celem pracy była ocena wpływu czasu trwania hospitalizacji na rokowanie u pacjentów z HF. 
Metody: W okresie od lutego 2012 do stycznia 2013 r. w 32 ośrodkach kardiologicznych w Polsce 1126 pacjentów z HF 
zostało włączonych do rejestru: EURObservational Research Programme on Heart Failure. 765 pacjentów było hospitalizo-
wanych. Przeprowadzono również obserwację (FU) pacjentów trwającą średnio 414 ± 121 dni.
Wyniki: Mediana czasu trwania hospitalizacji pacjentów wynosiła 7 dni (25–75 centyl; 4–11) Chorzy z nowo rozpoznaną 
HF (14,5% osób), jak również z przewlekłą postacią HF również byli hospitalizowani 7 dni (odpowiednio, 5–11 oraz 4–11). 
Czas trwania hospitalizacji u chorych, którzy zmarli w czasie FU (16,5%), i pacjentów, którzy ten okres przeżyli, wynosiła 
odpowiednio 8 dni (6–12) oraz 7 dni (4–10) (p < 0,001). U osób hospitalizowanych przez 8–21 dni oraz 22 dni lub więcej 
stwierdzono wyższe ryzyko zgonu po wypisaniu ze szpitala (odpowiednio, współczynnik ryzyka [HR] 1,70; 95% przedział 
ufności [CI] 1.16–2.49 oraz HR 2,20; 95% CI 1,04–4,67) niż pacjenci hospitalizowani do 7 dni. W analizie wieloczynnikowej 
czynnikami prognostycznymi śmiertelności były: wiek (HR 1,02; 95% CI 1,00–1,04), przewlekła choroba nerek w wywiadzie 
(HR 1,55; 95% CI 1,05–2,30), III klasa wg NYHA (HR 2,52; 95% CI 1,22–5,18) oraz IV klasa wg NYHA (HR 4,77; 95% CI 
2,32–9,82) przy przyjęciu. Pacjenci hospitalizowani 22 dni lub dłużej częściej byli płci męskiej (77%), mieli przewlekłą chorobę 
nerek (34%), przy przyjęciu mieli niższe ciśnienie tętnicze skurczowe (118 ± 25 mm Hg) oraz rozkurczowe (72 ± 12 mm Hg), 
a w badaniach laboratoryjnych wyższe stężenie NT-proBNP (9191 ± 8776 pg/ml), niższe stężenie sodu w osoczu krwi żylnej 
(137 ± 5 mmol/l) oraz niższą frakcję wyrzutową lewej komory przed przyjęciem oraz w trakcie pobytu w szpitalu (odpowiednio 
30 ± 12% i 34 ± 14%; dla wszystkich czynników p < 0,05). Czynnikami wpływającymi na czas trwania hospitalizacji były: 
przewlekła choroba nerek w wywiadzie (p < 0,001), obecna choroba nowotworowa (p = 0,026) oraz infekcja stwierdzona 
przy przyjęciu do szpitala (p < 0,001). U 45% pacjentów przyjętych do szpitala stwierdono III klasę wg NYHA (45%) HF. 
Chorzy z wyższą klasą wg NYHA przy przyjęciu byli dłużej hospitalizowani (p < 0,001). W okresie FU rehospitalizowano 
54% osób. Chorzy, którzy byli ponownie przyjęci do szpitala w czasie jednego roku od wypisania, charakteryzowali się takim 
samym czasem trwania hospitalizacji włączającej (mediana 7 dni [4–10]) co pacjenci bez rehospitalizacji w czasie jednego 
roku od wypisania (mediana 7 dni [4–11]; p = 0,957).
Wnioski: Pacjenci z HF hospitalizowani 22 dni lub dłużej, w porównaniu z chorymi, którzy przebywali w szpitalu krócej 
niż 8 dni, charakteryzowali się 2-krotnie większym ryzykiem zgonu w czasie FU. Na podstawie uzyskanych danych można 
stwierdzić, że przedłużona hospitalizacja może być markerem złego rokowania u chorych z ostrą HF. 
Słowa kluczowe: niewydolność serca, czas trwania hospitalizacji, rokowanie, śmiertelność
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